ライフサイエンスコーパス: antithrombotic agent

1 natural products, including vitisinol D, an antithrombotic agent.

2 tamin K antagonist that is widely used as an antithrombotic agent.

3 and recombinant ADAMTS13 could be used as an antithrombotic agent.

4 advantages over unfractionated heparin as an antithrombotic agent.

5 would be much more potent than aspirin as an antithrombotic agent.

6 alue as an analgesic, anti-inflammatory, and antithrombotic agent.

7 otidase activities, would constitute a novel antithrombotic agent.

8 Aspirin is a widely used and effective antithrombotic agent.

9 cular disease, including the frequent use of antithrombotic agents.

10 nhibitors may lead to the discovery of novel antithrombotic agents.

11 erol, smoking, physical activity, and use of antithrombotic agents.

12 accounting for the cAMP-directed activity of antithrombotic agents.

13 ere resistant to fibrinolysis or traditional antithrombotic agents.

14 nefit to bleeding risk profile over existing antithrombotic agents.

15 es that are not controlled with conventional antithrombotic agents.

16 present a new and potentially safer class of antithrombotic agents.

17 f adverse effects associated with the use of antithrombotic agents.

18 ists thus represent a potential new class of antithrombotic agents.

19 atelet aggregation in vivo and are potential antithrombotic agents.

20 thrombogenesis and are potentially useful as antithrombotic agents.

21 ation cascade and for the development of new antithrombotic agents.

22 basis for the development of a new class of antithrombotic agents.

23 elective antagonists are sought as potential antithrombotic agents.

24 ssociated with less bleeding risk than other antithrombotic agents.

25 s that block these receptors might be useful antithrombotic agents.

26 to have significant therapeutic potential as antithrombotic agents.

27 nd to explore the role of newer, more potent antithrombotic agents.

28 use of specific inhibitors of GPIIb-IIIa as antithrombotic agents.

29 at high risk for GIB after being prescribed antithrombotic agents.

30 thrombosis, details the current landscape of antithrombotic agents, addresses challenges with prevent

31 We hypothesized that antithrombotic agents alter the release of angiogenesis

32 K-MB-/cTn+ were treated similarly with early antithrombotic agents and catheter-based interventions.

33 The use of antithrombotic agents and invasive procedures reduces is

34 ventional pathways, and can be attenuated by antithrombotic agents and loss-of-function proteins (as

35 cluding standardized follow-up, imaging, and antithrombotic agents and then evaluated the most common

36 (abciximab; ReoPro) has been approved as an antithrombotic agent, and other GP IIb/IIIa antagonists,

37 nts on the combination of antihypertensives, antithrombotic agents, and lipid-lowering drugs (relativ

38 ts with ACS, exclusive of revascularization, antithrombotic agents, and the use of high-intensity sta

39 ntly awaited, and the possibility that other antithrombotic agents--and combinations thereof--have a

40 Antithrombotic agents are an integral component of the m

41 ew devices, new thrombolytic agents, and new antithrombotic agents are continuously being introduced

42 Antithrombotic agents are fundamental throughout the man

43 Antithrombotic agents are the cornerstone of secondary p

44 Information on the efficacy of newer antithrombotic agents as adjunct to thrombolysis or prim

45 Utility of antithrombotic agents (ATAs) in these settings is restri

46 rapeutics including antihypertensive agents, antithrombotic agents, beta-blocking agents, calcium cha

47 in could increase the therapeutic indices of antithrombotic agents by focusing on the destabilization

48 Antithrombotic agents can reduce the incidence of cerebr

49 12, a key microglial gene and target for the antithrombotic agent clopidogrel, as the likely driver o

50 Patients exposed to antithrombotic agents, compared with patients not expose

51 The cardiovascular and antithrombotic agent dipyridamole (DP) has potential the

52 g a potential clinical complication of novel antithrombotic agents directed toward the ITAM signaling

53 A variety of antithrombotic agents, doses, and durations of therapy a

54 e of this study was to determine the optimal antithrombotic agent for heart failure patients with red

55 been used clinically as an anticoagulant and antithrombotic agent for over 60 years.

56 they show promise as a safe and efficacious antithrombotic agent for PCI.

57 Finally, LMWHs show promise as an antithrombotic agent for the treatment of ST-elevation m

58 Finally, ADAMTS13 could be an antithrombotic agent for thrombotic thrombocytopenic pur

59 of FXIa with a focus on discovering an acute antithrombotic agent for use in a hospital setting.

60 ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coro

61 Development of effective, yet safe, antithrombotic agents has been challenging because such

62 vascular prevention has improved and use of antithrombotic agents has increased.

63 Although antithrombotic agents have potential in alleviating coca

64 ent with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin

65 nd avoidance of the concomitant use of other antithrombotic agents if feasible.

66 ing factors is currently being trialed as an antithrombotic agent in cancer patients.

67 t, may have therapeutic potential as an oral antithrombotic agent in coronary and carotid artery thro

68 ng definitions, and has become the preferred antithrombotic agent in the setting of acute coronary sy

69 lopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous cor

70 including ACE inhibitors, beta-blockers, and antithrombotic agents in addition to lipid-lowering agen

71 bitors, such as CVS-1123, may be alternative antithrombotic agents in clinical settings in which hepa

72 follow-up of 3 months or longer that tested antithrombotic agents in patients who have nonvalvular a

73 Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal

74 may offer therapeutic advantages over other antithrombotic agents in terms of bleeding complications

75 Recent studies on antithrombotic agents in this setting have highlighted t

76 They also proved to be potent anticoagulant/antithrombotic agents in vivo on intravenous administrat

77 ule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer.

78 pecial emphasis is given to recent trials of antithrombotic agents, including studies that have teste

79 Antithrombotic agents increase risks of intracerebral ha

80 Our data suggest that the mechanism by which antithrombotic agents increase survival and decrease met

81 While currently available antithrombotic agents inhibit either platelet aggregatio

82 inally, the clinical need for more effective antithrombotic agents is highlighted.

83 it was 3.5 (1.6 to 7.8), and for the use of antithrombotic agents it was 2.2 (1.0 to 4.8).

84 m antihypertensives agents, urologicals, and antithrombotic agents (macitentan, bosentan, epoprosteno

85 rinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk.

86 racerebral hemorrhage attends the use of all antithrombotic agents, most notably plasminogen activato

87 These advances include new antithrombotic agents, new options for dyslipidemia trea

88 tially replace unfractionated heparin as the antithrombotic agent of choice across the spectrum of AC

89 gulation (ie, placebo, open control, another antithrombotic agent, or another intervention for the pr

90 men) received at least 1 prescription for an antithrombotic agent over the study period.

91 rrelations shed light on mechanisms by which antithrombotic agents prevent stroke.

92 IA-H, treatment with bapineuzumab and use of antithrombotic agents provides additional support for th

93 Appropriate antithrombotic agent selection should be based on the be

94 even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogr

95 The currently available antithrombotic agents target the interaction of platelet

96 showed that Ir-CPI is an effective and safe antithrombotic agent that provides a clinically relevant

97 Antithrombotic agents that are inhibitors of factor XIa

98 sly demonstrated in a series of searches for antithrombotic agents that diadenosine 5',5"'-P1,P4-tetr

99 Antithrombotic agents that neutralize and inhibit polyph

100 ds offer a new platform for developing novel antithrombotic agents that target procoagulant anionic p

101 and safe alternative to currently available antithrombotic agents to restore vessel patency after ar

102 ines, glycoprotein IIb/IIIa inhibitors), and antithrombotic agents (unfractionated heparin and low-mo

103 son-years among patients actively exposed to antithrombotic agents vs 80.17 events per 1000 person-ye

104 Thus, a new antithrombotic agent was developed for platelet thrombus

105 The potential of 3 as antithrombotic agent was supported by its ability to inh

106 s containing corticosteroids, quetiapine, or antithrombotic agents were associated with the highest r

107 s containing corticosteroids, quetiapine, or antithrombotic agents were associated with the highest r

108 Antithrombin III (AT-III) is an antithrombotic agent with known anti-inflammatory proper

109 inhibitor of FXIa has the potential to be an antithrombotic agent with superior efficacy and safety.

110 The assessment of new antithrombotic agents with a favorable safety profile is